News and Announcements
CEO Dr James Garner interviewed for CommSec’s Executive Series
- Published October 29, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia’s CEO, Dr James Garner, was recently interviewed by Tom Piotrowski for CommSec’s Executive Series.
In the interview, Dr Garner discusses:
- Kazia’s recent $4mn capital raising, including the reasons behind the timing of the raise and why it was important to have the raise supported by specialist institutional investors.
- The Company’s recent efficacy data from its Cantrixil trial in ovarian cancer and the significance of treating patients in the later stages of the disease.
- The upcoming release of first efficacy data from Kazia’s phase II study of GDC-0084 in glioblastoma, expected in November.
- Kazia’s recent win in the inaugural ANZLF Trans-Tasman Innovation + Growth Awards.
For more information on Kazia’s recent capital raise, read the ASX Announcement here
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
